Kari M. Morrissey

2.6k citations

25 papers · 1.5k indexed · h-index 18

Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 6
Oncology top 5%
- Drug Transport and Resistance Mechanisms 9
- Cancer Immunotherapy and Biomarkers 3
Pediatrics, Perinatology and Child Health top 5%
- Pharmacological Effects and Toxicity Studies 3
Biological Psychiatry top 10%
- Tryptophan and brain disorders 3
Biochemistry top 5%
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 3
Behavioral Neuroscience
- Stress Responses and Cortisol 2
Genetics
- Chronic Lymphocytic Leukemia Research 2

Co-authors: Kathleen M. Giacomini Sophie L. Stocker Matthias Wittwer Lu Xu KM Giacomini Arik A. Zur S-M HuangL Zhang
Cited by: Pharmacology Oncology Pediatrics, Perinatology and Child Health
Journals: Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Oncology (1 paper)Bioinformatics (1 paper)
Partner nations: United States Netherlands Italy

In The Last Decade

Kari M. Morrissey

25 papers receiving 1.5k citations

Peers

Countries citing papers authored by Kari M. Morrissey

Since Specialization

Citations

This map shows the geographic impact of Kari M. Morrissey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari M. Morrissey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari M. Morrissey more than expected).

Fields of papers citing papers by Kari M. Morrissey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari M. Morrissey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari M. Morrissey. The network helps show where Kari M. Morrissey may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kari M. Morrissey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kari M. Morrissey Line = papers co-authored together Kari M. Morrissey links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors Nature Cancer ·Fiore Cattaruzza,Ayesha Nazeer,Milton To,Mikhail Hammond,Caitlin Koski,Lucas Y. Liu,V. Pete Yeung,Deena A. Rennerfeldt,Angela Henkensiefken,Michael Fox,Sharon Lam,Kari M. Morrissey,Zachary Lange,Vladimir N. Podust,Mika K. Derynck,Bryan Irving,Volker Schellenberger	2023	50
2	Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate) Molecular Cancer Therapeutics ·Milton To,Pete Yeung,Michael Fox,Mikhail Hammond,Fiore Cattaruzza,Ayesha Nazeer,Caitlin Koski,Lucas Liu,Sina Khorsand,Deena A. Rennerfeldt,Kari M. Morrissey,Zachary Lange,Ming Dong,Sharon Lam,Mika K. Derynck,Bryan Irving,Volker Schellenberger	2021	4
3	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting Cancer Chemotherapy and Pharmacology ·Kari M. Morrissey,Mathilde Marchand,Hina Patel,Rong Zhang,Benjamin Wu,H. Phyllis Chan,Almut Mecke,Sandhya Girish,Jin Y. Jin,Helen Winter,René Bruno	2019	62
4	Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor British Journal of Clinical Pharmacology ·Shuguang Ma,Julia Suchomel,Evelyn Yanez,Edward Yost,Xiaorong Liang,Rui Zhu,Hoa Thi Le,Nicholas Siebers,Lori Joas,Roland Morley,Stephanie Royer‐Joo,Andrea Pirzkall,Laurent Salphati,Joseph A. Ware,Kari M. Morrissey	2019	17
5	The Patient‐Centered Future of Clinical Pharmacology Clinical Pharmacology & Therapeutics ·Mohamed H. Shahin,Susan M. Abdel‐Rahman,Dan Hartman,Julie A. Johnson,David Mitchell,Kellie S. Reynolds,John A. Wagner,Kari M. Morrissey	2019	4
6	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer Breast Cancer Research ·Patrick Schöffski,Sara Cresta,Ingrid A. Mayer,Hans Wildiers,Silvia Damian,Steven Gendreau,Isabelle Rooney,Kari M. Morrissey,Jill M. Spoerke,Vivian Ng,Stina Mui Singel,Eric P. Winer	2018	67
7	Computational analysis of kinase inhibitor selectivity using structural knowledge Bioinformatics ·Yu-Chen Lo,Tianyun Liu,Kari M. Morrissey,Satoko Kakiuchi-Kiyota,Adam R. Johnson,Fabio Broccatelli,Yu Zhong,Amita Joshi,Russ B. Altman	2018	17
8	A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer European Journal of Cancer ·Jean‐Charles Soria,Alex A. Adjei,Rastilav Bahleda,Benjamin Besse,Charles Ferté,David Planchard,Jing Zhou,Joseph A. Ware,Kari M. Morrissey,Geetha Shankar,Wei-Chun Lin,Jennifer L. Schutzman,Grace K. Dy,Harry J.M. Groen	2017	28
9	Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics CPT Pharmacometrics & Systems Pharmacology ·Tong Lu,Grazyna Fraczkiewicz,Laurent Salphati,Nageshwar Budha,Gena Dalziel,Gillian S. Smelick,Kari M. Morrissey,John D. Davis,Jin Y. Jin,Joseph A. Ware	2017	8
10	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers Clinical Pharmacokinetics ·Kari M. Morrissey,Sophie L. Stocker,Eugene C. Chen,Richard A. Castro,Claire M. Brett,Kathleen M. Giacomini	2015	29
11	346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors European Journal of Cancer ·Anupama Nayak,Zhonglin Hao,Ramses Sadek,Robin Dobbins,Lisa J. Marshall,Nicholas N. Vahanian,Jay Ramsey,Eugene P. Kennedy,Mario R. Mautino,Charles Link,Ray Lin,Stephanie Royer‐Joo,Kari M. Morrissey,Sami Mahrus,B. McCall,Andrea Pirzkall,David H. Munn,John E. Janik,Samir N. Khleif	2015	14
12	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin Proceedings of the National Academy of Sciences ·Ligong Chen,Yan Shu,Xiaomin Liang,Eugene C. Chen,Sook Wah Yee,Arik A. Zur,Shuanglian Li,Lu Xu,Kayvan R. Keshari,Michael J. Lin,Huan‐Chieh Chien,Youcai Zhang,Kari M. Morrissey,Jason Liu,J.M. Ostrem,Noah Younger,John Kurhanewicz,Kevan M. Shokat,Kaveh Ashrafi,Kathleen M. Giacomini	2014	182
13	Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements PLoS Genetics ·Robin P. Smith,Walter L. Eckalbar,Kari M. Morrissey,Marcelo R. Luizon,Thomas J. Hoffmann,Xuefeng Sun,Stacy L. Jones,Shelley Force Aldred,Anuradha Ramamoorthy,Zeruesenay Desta,Yunlong Liu,Todd C. Skaar,Nathan D. Trinklein,Kathleen M. Giacomini,Nadav Ahituv	2014	38
14	The UCSF-FDA TransPortal: A Public Drug Transporter Database Clinical Pharmacology & Therapeutics ·Kari M. Morrissey,C C Wen,Susan J. Johns,L Zhang,S-M Huang,KM Giacomini	2012	126
15	The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin Clinical Pharmacology & Therapeutics ·Sophie L. Stocker,Kari M. Morrissey,Sook Wah Yee,R A Castro,Lijun Xu,Amber Dahlin,Andrea H. Ramirez,Dan M. Roden,Russell A. Wilke,Catherine A. McCarty,Robert L. Davis,Christopher M. A. Brett,KM Giacomini	2012	130
16	Renal Transporters in Drug Development The Annual Review of Pharmacology and Toxicology ·Kari M. Morrissey,Sophie L. Stocker,Matthias Wittwer,Lu Xu,Kathleen M. Giacomini	2012	248
17	Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro Pharmacogenetics and Genomics ·Duanpen Sandee,Kari M. Morrissey,Vishal Agrawal,Harrison K. Tam,Melissa A. Kramer,Timothy S. Tracy,Kathleen M. Giacomini,Walter L. Miller	2010	62
18	Consequences of POR mutations and polymorphisms Molecular and Cellular Endocrinology ·Walter L. Miller,Vishal Agrawal,Duanpen Sandee,Meng Kian Tee,Ningwu Huang,Ji Ha Choi,Kari M. Morrissey,Kathleen M. Giacomini	2010	60
19	Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction Drug Metabolism and Disposition ·Magang Shou,Mike Hayashi,Yvonne Pan,Yang Xu,Kari M. Morrissey,Lilly Xu,Gary L. Skiles	2008	102
20	Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus Traffic ·Jessica R. Colantonio,Janine M. Bekker,Sarah J. Kim,Kari M. Morrissey,Rachelle H. Crosbie,Kent L. Hill	2006	13

About Kari M. Morrissey

Kari M. Morrissey is a scholar working on Biological Psychiatry, Pharmacology and Oncology, having authored 25 papers that have together received 1.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacogenetics and Drug Metabolism (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Pharmacological Effects and Toxicity Studies (3 papers), Tryptophan and brain disorders (3 papers), Stress Responses and Cortisol (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Pharmacology (334 citations), Oncology (777 citations) and Pediatrics, Perinatology and Child Health (336 citations). Kari M. Morrissey has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Kathleen M. Giacomini, Sophie L. Stocker, Matthias Wittwer, Lu Xu, KM Giacomini, Arik A. Zur, S-M Huang, L Zhang, Susan J. Johns and Sook Wah Yee. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Bioinformatics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact